• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

逆转录病毒整合研究及相关国际会议简史

Brief Histories of Retroviral Integration Research and Associated International Conferences.

作者信息

Grandgenett Duane P, Engelman Alan N

机构信息

Department of Molecular Microbiology and Immunology, School of Medicine, Saint Louis University, St. Louis, MO 63104, USA.

Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

出版信息

Viruses. 2024 Apr 13;16(4):604. doi: 10.3390/v16040604.

DOI:10.3390/v16040604
PMID:38675945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11054761/
Abstract

The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes. Because both enzymes are essential for retroviral replication, they became valued targets in the effort to discover effective compounds to inhibit HIV-1 replication. In 2007, the first integrase strand transfer inhibitor was licensed for clinical use, and subsequently approved second-generation integrase inhibitors are now commonly co-formulated with reverse transcriptase inhibitors to treat people living with HIV. International meetings specifically focused on integrase and retroviral integration research first convened in 1995, and this paper is part of the Special Issue on the 7th International Conference on Retroviral Integration, which was held in Boulder Colorado in the summer of 2023. Herein, we overview key historical developments in the field, especially as they pertain to the development of the strand transfer inhibitor drug class. Starting from the mid-1990s, research advancements are presented through the lens of the international conferences. Our overview highlights the impact that regularly scheduled, subject-specific international meetings can have on community-building and, as a result, on field-specific collaborations and scientific advancements.

摘要

逆转录病毒整合研究领域有着悠久的历史,始于前病毒假说以及随后逆转录病毒逆转录酶和整合酶的发现。由于这两种酶对于逆转录病毒复制至关重要,它们成为了发现抑制HIV-1复制的有效化合物的重要靶点。2007年,首个整合酶链转移抑制剂获批用于临床,随后获批的第二代整合酶抑制剂现在通常与逆转录酶抑制剂联合配方,用于治疗HIV感染者。专门聚焦于整合酶和逆转录病毒整合研究的国际会议于1995年首次召开,本文是2023年夏天在科罗拉多州博尔德市举行的第七届逆转录病毒整合国际会议特刊的一部分。在此,我们概述该领域的关键历史发展,尤其是与链转移抑制剂药物类别的发展相关的方面。从20世纪90年代中期开始,通过国际会议的视角呈现研究进展。我们的概述突出了定期举行的、特定主题的国际会议对社群建设的影响,以及由此对特定领域的合作和科学进步的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/19b8454d9c86/viruses-16-00604-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/e69e627ef5c5/viruses-16-00604-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/ea65e37f79cc/viruses-16-00604-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/cad87b45afaa/viruses-16-00604-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/19b8454d9c86/viruses-16-00604-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/e69e627ef5c5/viruses-16-00604-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/ea65e37f79cc/viruses-16-00604-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/cad87b45afaa/viruses-16-00604-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7103/11054761/19b8454d9c86/viruses-16-00604-g004.jpg

相似文献

1
Brief Histories of Retroviral Integration Research and Associated International Conferences.逆转录病毒整合研究及相关国际会议简史
Viruses. 2024 Apr 13;16(4):604. doi: 10.3390/v16040604.
2
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.突变位于整合酶基因之外可赋予 HIV-1 整合酶链转移抑制剂耐药性。
mBio. 2017 Sep 26;8(5):e00922-17. doi: 10.1128/mBio.00922-17.
3
A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.HIV 整合酶链转移抑制剂(INSTIs)在预防和治疗 HIV-1 感染方面的临床评价。
Retrovirology. 2022 Oct 22;19(1):22. doi: 10.1186/s12977-022-00608-1.
4
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.HIV-1 整合酶链转移抑制剂的比较临床药代动力学和药效学:更新综述。
Clin Pharmacokinet. 2020 Sep;59(9):1085-1107. doi: 10.1007/s40262-020-00898-8.
5
A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.人类免疫缺陷病毒 2 型对整合酶抑制剂产生耐药性的新机制:整合酶 C 末端结构域的 5 个氨基酸插入。
Clin Infect Dis. 2019 Aug 1;69(4):657-667. doi: 10.1093/cid/ciy940.
6
The future of integrase inhibitors of HIV-1.HIV-1 整合酶抑制剂的未来。
Curr Opin Virol. 2012 Oct;2(5):580-7. doi: 10.1016/j.coviro.2012.08.005. Epub 2012 Sep 12.
7
HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.HIV-1整合酶链转移抑制剂:当前药物、最新进展及耐药性综述
Int J Antimicrob Agents. 2021 May;57(5):106343. doi: 10.1016/j.ijantimicag.2021.106343. Epub 2021 Apr 11.
8
Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.临床观察到的 HIV 整合酶突变组合对整合酶链转移抑制剂(INSTIs)表型耐药性的影响:一项分子研究。
J Antimicrob Chemother. 2022 Mar 31;77(4):979-988. doi: 10.1093/jac/dkab498.
9
New first and second generation inhibitors of human immunodeficiency virus-1 integrase.新型人免疫缺陷病毒-1 整合酶的第一代和第二代抑制剂。
Expert Opin Ther Pat. 2011 Aug;21(8):1173-89. doi: 10.1517/13543776.2011.586631. Epub 2011 May 20.
10
Assessing phenotypic effect of integrase strand-transfer inhibitor (INSTI)-based resistance substitutions associated with failures on cabotegravir.评估与卡博特韦治疗失败相关的基于整合酶链转移抑制剂(INSTI)的耐药性替代的表型效应。
J Antimicrob Chemother. 2025 Apr 2;80(4):962-966. doi: 10.1093/jac/dkaf019.

引用本文的文献

1
Switching to Long-Acting Cabotegravir and Rilpivirine in Turkey: Perspectives from People Living with HIV in a Setting of Increasing HIV Incidence.在土耳其改用长效卡博特韦和rilpivirine:在艾滋病毒发病率不断上升的背景下,艾滋病毒感染者的观点。
Medicina (Kaunas). 2025 Jul 29;61(8):1373. doi: 10.3390/medicina61081373.
2
Retrointegration2023-Papers from the 7th International Conference on Retroviral Integration.《逆转录病毒整合2023——第七届逆转录病毒整合国际会议论文集》
Viruses. 2025 Jun 23;17(7):879. doi: 10.3390/v17070879.
3
Biological Barriers for Drug Delivery and Development of Innovative Therapeutic Approaches in HIV, Pancreatic Cancer, and Hemophilia A/B.

本文引用的文献

1
"Block and lock" viral integration sites in persons with drug-free control of HIV-1 infection.在未接受药物治疗即可控制 HIV-1 感染的个体中“封锁和锁定”病毒整合部位。
Curr Opin HIV AIDS. 2024 May 1;19(3):110-115. doi: 10.1097/COH.0000000000000845. Epub 2024 Feb 28.
2
Epistatic pathways can drive HIV-1 escape from integrase strand transfer inhibitors.上位途径可驱动 HIV-1 逃避整合酶链转移抑制剂。
Sci Adv. 2024 Mar;10(9):eadn0042. doi: 10.1126/sciadv.adn0042. Epub 2024 Mar 1.
3
KuINins as a New Class of HIV-1 Inhibitors That Block Post-Integration DNA Repair.
药物递送的生物屏障以及针对HIV、胰腺癌和甲型/乙型血友病的创新治疗方法的开发
Pharmaceutics. 2024 Sep 13;16(9):1207. doi: 10.3390/pharmaceutics16091207.
4
HPV, HBV, and HIV-1 Viral Integration Site Mapping: A Streamlined Workflow from NGS to Genomic Insights of Carcinogenesis.HPV、HBV 和 HIV-1 病毒整合位点作图:从 NGS 到致癌基因组见解的简化工作流程。
Viruses. 2024 Jun 18;16(6):975. doi: 10.3390/v16060975.
KuIN 作为一种新型 HIV-1 抑制剂,可阻断整合后 DNA 修复。
Int J Mol Sci. 2023 Dec 11;24(24):17354. doi: 10.3390/ijms242417354.
4
Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants.HIV-1 整合酶对多替拉韦的耐药机制及对耐药变异体的强效抑制作用。
Sci Adv. 2023 Jul 21;9(29):eadg5953. doi: 10.1126/sciadv.adg5953.
5
DNA topoisomerase 1 represses HIV-1 promoter activity through its interaction with a guanine quadruplex present in the LTR sequence.DNA 拓扑异构酶 1 通过与 LTR 序列中存在的鸟嘌呤四链体相互作用来抑制 HIV-1 启动子活性。
Retrovirology. 2023 May 30;20(1):10. doi: 10.1186/s12977-023-00625-8.
6
HIV-1 3'-Polypurine Tract Mutations Confer Dolutegravir Resistance by Switching to an Integration-Independent Replication Mechanism via 1-LTR Circles.HIV-1 3'-端多聚嘧啶区突变通过 1-LTR 环切换为整合非依赖型复制机制从而赋予对多替拉韦的耐药性。
J Virol. 2023 May 31;97(5):e0036123. doi: 10.1128/jvi.00361-23. Epub 2023 May 1.
7
Both ATM and DNA-PK Are the Main Regulators of HIV-1 Post-Integrational DNA Repair.ATM 和 DNA-PK 均为 HIV-1 整合后 DNA 修复的主要调控因子。
Int J Mol Sci. 2023 Feb 1;24(3):2797. doi: 10.3390/ijms24032797.
8
Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.不同途径导致整合酶链转移抑制剂耐药。
Viruses. 2022 Nov 22;14(12):2591. doi: 10.3390/v14122591.
9
Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration.3'-PPT 突变导致 HIV-1 复制而不整合。
J Virol. 2022 Jul 27;96(14):e0067622. doi: 10.1128/jvi.00676-22. Epub 2022 Jun 27.
10
HIV-1 exploits the Fanconi anemia pathway for viral DNA integration.HIV-1 利用范可尼贫血途径进行病毒 DNA 整合。
Cell Rep. 2022 May 24;39(8):110840. doi: 10.1016/j.celrep.2022.110840.